Advertisment

Cefepime-Taniborbactam: A New Hope in the Treatment of Complicated UTIs and Acute Pyelonephritis

author-image
Ayanna Amadi
New Update
NULL

Cefepime-Taniborbactam: A New Hope in the Treatment of Complicated UTIs and Acute Pyelonephritis

Advertisment

Urinary tract infections (UTIs) and acute pyelonephritis, if left untreated or improperly managed, can lead to severe complications and distressing symptoms. The search for effective treatments for these conditions has led researchers to investigate the potential of a new drug combination, Cefepime-Taniborbactam.

Advertisment

A Remarkable Study

A study published in The New England Journal of Medicine (NEJM), led by Paul McGovern, MD, an infectious disease specialist and senior vice president of Venatorx Pharmaceuticals, found that Cefepime-Taniborbactam was 22% more effective than the current standard treatment, meropenem, in treating complicated UTIs and acute pyelonephritis. This study didn't report any limitations and was funded by Venatorx Pharmaceuticals, with support from various organizations including the US Department of Health and Human Services.

About Cefepime-Taniborbactam

Advertisment

Cefepime-Taniborbactam is an investigational β-lactam and β-lactamase inhibitor combination drug. It has shown activity against Enterobacterales species and P. aeruginosa, both of which express serine and metallo-β-lactamases. These species are often implicated in complicated UTIs and acute pyelonephritis, making this drug combination a promising new treatment option.

Details of the Study

The research was a phase 3, double-blind, randomized trial involving hospitalized adults. The primary outcome was both microbiologic and clinical success. Remarkably, the study found Cefepime-Taniborbactam to be superior to meropenem regarding this primary outcome. It's worth noting that the safety profile of Cefepime-Taniborbactam was similar to that of meropenem, further establishing its potential as a reliable treatment option.

Advertisment

Efficacy and Adverse Events

The composite microbiologic and clinical success rate with Cefepime-Taniborbactam was 70.6%, compared to 58% with meropenem. This shows a significant improvement in the treatment of complicated UTIs and acute pyelonephritis. Furthermore, the drug was found to have sustained efficacy for up to a month after treatment.

Adverse events occurred in 35.5% of the Cefepime-Taniborbactam group, compared to 29.0% in the meropenem group. The most frequently reported adverse events in the Cefepime-Taniborbactam group included headache, gastrointestinal events, and hypertension. Serious adverse events occurred in 2.0% of the Cefepime-Taniborbactam group and 1.8% in the meropenem group, indicating a comparable safety profile between the two treatments.

Conclusion

The study concluded that Cefepime-Taniborbactam is a potential treatment option for patients with complicated UTIs and acute pyelonephritis caused by Enterobacterales species and Pseudomonas aeruginosa, including antimicrobial-resistant strains. This promising development offers hope for the effective management and treatment of these debilitating conditions.

Advertisment
Chat with Dr. Medriva !